Barclays Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

Key Points

• Barclays raised Merck’s price target from $150 to $180 and maintained an “overweight” rating, implying approximately 27% upside from the reported share price of $141.72.
• Analyst sentiment is broadly positive: Merck has a “Moderate Buy” consensus rating, with 17 Buy, 9 Hold and 1 Sell recommendation; the consensus price target is $153.12.
• Merck exceeded quarterly earnings and revenue expectations, reporting adjusted EPS of ($0.13) versus an expected ($0.26) and revenue of $16.61 billion, up 5.1% year over year. Institutional investors own approximately 76.07% of the company, while insiders sold about $30 million in shares over the past 90 days.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) had its price target increased by stock analysts at Barclays from $150.00 to $180.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Barclays's target price would indicate a potential upside of 27.01% from the company's current price.

Several other research analysts also recently weighed in on the company. Wolfe Research lifted their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an "outperform" rating in a research note on Tuesday, August 25th. Sanford C. Bernstein boosted their price target on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a "market perform" rating in a research note on Tuesday, August 4th. BMO Capital Markets boosted their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a research report on Thursday, August 20th. Argus upped their price objective on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a "buy" rating in a report on Tuesday, August 25th. Finally, HSBC raised their target price on Merck & Co., Inc. from $150.00 to $172.00 and gave the company a "buy" rating in a report on Thursday, September 10th. Seventeen investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and a consensus target price of $153.12.

Merck & Co., Inc. Stock Performance

NYSE:MRK traded down $3.55 during mid-day trading on Monday, reaching $141.72. 2,275,120 shares of the stock were exchanged, compared to its average volume of 10,620,148. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The stock has a market capitalization of $349.64 billion, a P/E ratio of 113.32, a P/E/G ratio of 6.74 and a beta of 0.21. The company has a 50 day simple moving average of $146.98 and a 200-day simple moving average of $130.24. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to analysts' expectations of $16.37 billion. During the same period in the previous year, the company posted $2.13 EPS. The company's quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts anticipate that Merck & Co., Inc. will post 2.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of Merck & Co., Inc. stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares in the company, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Chirfi Guindo sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares of the company's stock, valued at approximately $4,942,755. This trade represents a 21.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by company insiders.

Institutional Investors Weigh In On Merck & Co., Inc.

Large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its stake in Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company's stock worth $1,858,938,000 after buying an additional 2,969,856 shares during the period. Bank of America Corp DE lifted its holdings in shares of Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company's stock valued at $3,701,831,000 after acquiring an additional 2,919,780 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Merck & Co., Inc. by 263.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 2,702,992 shares of the company's stock worth $347,334,000 after purchasing an additional 1,959,778 shares during the period. Wellington Management Group LLP increased its holdings in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares in the last quarter. Finally, SEB Asset Management AB purchased a new position in Merck & Co., Inc. in the first quarter valued at about $197,550,000. Institutional investors and hedge funds own 76.07% of the company's stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck's principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.